Literature DB >> 17145783

Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.

Charalampos Antachopoulos1, Joseph Meletiadis, Tin Sein, Emmanuel Roilides, Thomas J Walsh.   

Abstract

The minimum effective concentration (MEC) used to assess the in vitro antifungal activity of caspofungin against Aspergillus spp. is a qualitative endpoint requiring microscopic examination of hyphae. We therefore developed a tool for the quantitative assessment of caspofungin activity against Aspergillus spp. at clinically applicable concentrations. Susceptibility to caspofungin (0.008 to 8 microg/ml) was studied for 9 A. fumigatus, 8 A. flavus, and 12 A. terreus isolates based on the Clinical and Laboratory Standards Institute M38-A protocol. After 48 h of incubation, the MEC was defined microscopically, and metabolic activity assessed with a modified XTT assay, using 100 microg of the tetrazolium salt XTT/ml and 6.25 muM menadione. A significant reduction in metabolic activity was demonstrated at the MEC (0.25 to 0.5 microg/ml) for all Aspergillus spp. and was more pronounced for A. flavus (median metabolic activity, 25% of control) compared to A. fumigatus and A. terreus (median metabolism, 42 and 53%, respectively), allowing determination of MEC with the XTT assay (93 to 100% agreement with microscopic MEC). Fungal metabolism tended to reach the lowest levels (median, 17 to 38% of control) one to two dilutions higher than the MEC, at the minimum metabolic activity concentration (MMC). For 5 of 9 A. fumigatus isolates, 6 of 12 A. terreus isolates, and 1 of 8 A. flavus isolates, a paradoxical increase in metabolism was observed at concentrations greater than the MMC. Sigmoid (E(max)) or bell-shaped models described accurately (median R(2) = 0.97) the concentration-dependent metabolic changes in the absence or presence, respectively, of paradoxical response. Assessment of metabolic activity may provide useful quantitative endpoints for in vitro studies of caspofungin against Aspergillus spp.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145783      PMCID: PMC1803126          DOI: 10.1128/AAC.01160-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin.

Authors:  R E Gardiner; P Souteropoulos; S Park; D S Perlin
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

2.  Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin.

Authors:  David A Stevens; Masayuki Ichinomiya; Yukako Koshi; Hiroyuki Horiuchi
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.

Authors:  Johan Maertens; Issam Raad; George Petrikkos; Marc Boogaerts; Dominik Selleslag; Finn B Petersen; Carole A Sable; Nicholas A Kartsonis; Angela Ngai; Arlene Taylor; Thomas F Patterson; David W Denning; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

4.  Efficacy of caspofungin against Aspergillus terreus.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Alfredo Santinelli; Annette W Fothergill; Stefania Fallani; Esther Manso; Eleonora Pisa; Daniele Giannini; Andrea Novelli; Maria I Cassetta; Teresita Mazzei; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection.

Authors:  Anthony Cacciapuoti; Judith Halpern; Cara Mendrick; Christine Norris; Reena Patel; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

6.  Relationship between metabolism and biomass of medically important zygomycetes.

Authors:  Charalampos Antachopoulos; Joseph Meletiadis; Emmanuel Roilides; Tin Sein; Deanna A Sutton; Brian L Wickes; Michael G Rinaldi; William G Merz; Yvonne R Shea; Thomas J Walsh
Journal:  Med Mycol       Date:  2006-08       Impact factor: 4.076

7.  Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.

Authors:  Thomas J Walsh; Peter C Adamson; Nita L Seibel; Patricia M Flynn; Michael N Neely; Cindy Schwartz; Aziza Shad; Sheldon L Kaplan; Maureen M Roden; Julie A Stone; Alisha Miller; Susan K Bradshaw; Susan X Li; Carole A Sable; Nicholas A Kartsonis
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  Assessment of the paradoxical effect of caspofungin in therapy of candidiasis.

Authors:  Karl V Clemons; Marife Espiritu; Rachana Parmar; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

9.  Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.

Authors:  M B Kurtz; I B Heath; J Marrinan; S Dreikorn; J Onishi; C Douglas
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

10.  Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.

Authors:  Wim van Vianen; Siem de Marie; Marian T ten Kate; Ron A A Mathot; Irma A J M Bakker-Woudenberg
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

View more
  22 in total

1.  The composition of the culture medium influences the β-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of β-1,3-glucan synthesis.

Authors:  Cécile Clavaud; Anne Beauvais; Lise Barbin; Hélène Munier-Lehmann; Jean-Paul Latgé
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

2.  Role of innate immune receptors in paradoxical caspofungin activity in vivo in preclinical aspergillosis.

Authors:  Silvia Moretti; Silvia Bozza; Carmen D'Angelo; Andrea Casagrande; Maria Agnese Della Fazia; Lucia Pitzurra; Luigina Romani; Franco Aversa
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

Review 3.  Echinocandins for the Treatment of Invasive Aspergillosis: from Laboratory to Bedside.

Authors:  Marion Aruanno; Emmanouil Glampedakis; Frédéric Lamoth
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Role of trehalose biosynthesis in Aspergillus fumigatus development, stress response, and virulence.

Authors:  Nadia Al-Bader; Ghyslaine Vanier; Hong Liu; Fabrice N Gravelat; Mirjam Urb; Christopher M-Q Hoareau; Paolo Campoli; Joseé Chabot; Scott G Filler; Donald C Sheppard
Journal:  Infect Immun       Date:  2010-05-03       Impact factor: 3.441

5.  Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination.

Authors:  Patricia E B Verwer; M L van Duijn; M Tavakol; Irma A J M Bakker-Woudenberg; Wendy W J van de Sande
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

6.  Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins.

Authors:  Maria Siopi; Spyros Pournaras; Joseph Meletiadis
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

Review 7.  Echinocandin antifungal drugs in fungal infections: a comparison.

Authors:  Sharon C-A Chen; Monica A Slavin; Tania C Sorrell
Journal:  Drugs       Date:  2011-01-01       Impact factor: 9.546

8.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

9.  Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model.

Authors:  Joseph Meletiadis; Theodouli Stergiopoulou; Elizabeth M O'Shaughnessy; Joanne Peter; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

10.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.